--- title: "Trustmark Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year" type: "News" locale: "en" url: "https://longbridge.com/en/news/294507012.md" description: "Trustmark Corporation (NASDAQ:TRMK) beat analyst estimates with a statutory profit of US$1.08 per share, 12% above expectations, while revenues matched forecasts at US$211m. Analysts upgraded their 2026 EPS forecast to US$4.03 from US$3.91, reflecting increased optimism, though revenue estimates remained largely unchanged at US$848.5m. The consensus price target held steady at US$49.25. Trustmark's expected revenue growth of 8.2% annually through 2026 aligns with industry averages." datetime: "2026-07-31T11:33:22.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294507012.md) - [en](https://longbridge.com/en/news/294507012.md) - [zh-HK](https://longbridge.com/zh-HK/news/294507012.md) generator: "portal-rs" --- # Trustmark Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year Last week saw the newest quarterly earnings release from **Trustmark Corporation** (NASDAQ:TRMK), an important milestone in the company's journey to build a stronger business. It looks like a credible result overall - although revenues of US$211m were in line with what the analysts predicted, Trustmark surprised by delivering a statutory profit of US$1.08 per share, a notable 12% above expectations. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. NasdaqGS:TRMK Earnings and Revenue Growth July 31st 2026 Taking into account the latest results, the current consensus from Trustmark's five analysts is for revenues of US$848.5m in 2026. This would reflect a modest 4.0% increase on its revenue over the past 12 months. Statutory per-share earnings are expected to be US$4.03, roughly flat on the last 12 months. Before this earnings report, the analysts had been forecasting revenues of US$850.8m and earnings per share (EPS) of US$3.91 in 2026. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates. See our latest analysis for Trustmark The consensus price target was unchanged at US$49.25, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Trustmark at US$54.25 per share, while the most bearish prices it at US$47.00. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Trustmark is an easy business to forecast or the the analysts are all using similar assumptions. Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Trustmark's rate of growth is expected to accelerate meaningfully, with the forecast 8.2% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 2.0% p.a. over the past five years. Other similar companies in the industry (with analyst coverage) are also forecast to grow their revenue at 7.8% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Trustmark is expected to grow at about the same rate as the wider industry. ## The Bottom Line The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Trustmark following these results. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at US$49.25, with the latest estimates not enough to have an impact on their price targets. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Trustmark analysts - going out to 2027, and you can see them free on our platform here. You can also view our analysis of Trustmark's balance sheet, and whether we think Trustmark is carrying too much debt, for free on our platform here. ### Valuation is complex, but we're here to simplify it. Discover if Trustmark might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [TRMK.US](https://longbridge.com/en/quote/TRMK.US.md) ## Related News & Research - [Bank of America Corp DE Acquires 173,486 Shares of Trustmark Corporation $TRMK](https://longbridge.com/en/news/296675221.md) - [Trustmark (TRMK) Stock Profit Beat Masks Valuation And Core Earnings Questions](https://longbridge.com/en/news/294273253.md) - [1,952,930 Shares in Trustmark Corporation $TRMK Purchased by North Reef Capital Management LP](https://longbridge.com/en/news/293843584.md) - [Crude Prices Supported by Dollar Weakness and Middle East Tensions](https://longbridge.com/en/news/296376829.md) - [Trustmark Q2 net earnings rises on higher net interest income](https://longbridge.com/en/news/294111806.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**